Human Interferon-Induced Double Stranded RNA-Activated Protein Kinase (EIF2AK2) Protein

832€ (50 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Human Interferon-Induced Double Stranded RNA-Activated Protein Kinase (EIF2AK2) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx651433
tested applications
WB, SDS-PAGE
Description
Human Interferon-Induced Double Stranded RNA-Activated Protein Kinase (EIF2AK2) Protein (Active) is a recombinant active Human protein expressed in E. coli.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Interferon-Induced Double Stranded RNA-Activated Protein Kinase (EIF2AK2) |
| Host | E. coli |
| Assay Type | Activity: Active Biological Activity: Protein Kinase R (PKR) is activated by double-stranded RNA (dsRNA), the synthesis of which is caused by viruses. PKR can also be activated by the protein PACT or by heparain. It plays a key role in the innate immune response to viral infection and is also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation. Cyclin Dependent Kinase 1 (CDK1) has been identified as an interactor of PKR, thus a binding ELISA assay was conducted to detect the interaction of recombinant human PKR and recombinant human CDK1. Briefly, PKR was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to CDK1-coated microplate wells and incubated for 2 h at 37°C. Wells were washed with PBST and incubated for 1 h with anti-PKR polyclonal antibody, then aspirated and washed 3 times. After incubation with HRP-conjugated secondary antibody, wells were aspirated and washed 3 times. TMB substrate solution was added and wells were incubated for 15-25 minutes at 37 °C. Finally, 50 μl stop solution was added to the wells and the absorbance was read at 450 nm immediately. Sequence Fragment: Ser224-Ile502 Tag: N-terminal His tag |
| Origin | Human |
| Conjugation | Unconjugated |
| Observed MW | Calculated MW: 35.8 kDa Observed MW: 32 kDa Possible reasons why the actual band size differs from the predicted band size: 1. Splice variants. Alternative splicing may create different sized proteins from the same gene. 2. Relative charge. The composition of amino acids may affect the charge of the protein. 3. Post-translational modification. Phosphorylation, glycoslyation, methylation etc. may affect the band size. 4. Post-translational cleavage. Many proteins are synthesised as pro-proteins, and then cleaved to give the active form. 5. Polymerisation of the target protein. Dimerisation, multimerisation etc. will increase the band size observed. |
| Expression | Recombinant |
| Purity | > 80% |
| Size 1 | 50 µg |
| Size 2 | 100 µg |
| Size 3 | 200 µg |
| Size 4 | 500 µg |
| Size 5 | 1 mg |
| Form | Lyophilized |
| Tested Applications | WB, SDS-PAGE |
| Buffer | Prior to lyophilization: 20 mM Tris, 150 mM NaCl, pH 8.0, containing 0.01% Sarcosyl, 5% Trehalose. |
| Availability | Shipped within 5-7 working days. |
| Storage | Store lyophilized form at 2-8°C for up to 1 month. For longer periods, store lyophilized or liquid at -80°C. Avoid repeated freeze–thaw cycles. |
| Dry Ice | No |
| UniProt ID | P19525 |
| Background | Protein EIF2AK2 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. Reconstitute in ddH2O to a concentration between 0.1-1.0 mg/ml. Do not vortex. Endotoxin Level: < 1.0 EU/µg (LAL method) Concentration: Prior to lyophilization: 200 µg/ml |
Descripción
Related Products

Human EIF2AK2 (Interferon-induced, double-stranded RNA-activated protein kinase) ELISA Kit
Ver Producto
EIF2AK2 antibody
Ver Producto